HURA at a glance
TuHURA Biosciences, Inc./NV (HURA, SEC CIK 1498382) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and a net loss of $30.1 million. Diluted EPS was -$0.63.
- As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding TuHURA Biosciences, Inc./NV (HURA) shares worth $9.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 17 funds
- $9.5M · +0 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 2.03
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors since the 2025 Form 10-K
- No newly added risk factor identified this quarter
- Carried-forward risks remain those disclosed in the 2025 Form 10-K and March 31, 2026 Form 10-Q
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no products approved for sale
- Net loss $6.4M vs $7.1M YoY, operating loss $5.7M vs $6.7M
- Best program TBS-2025 R&D $0.4M, up $0.1M; IFx-2.0 $1.1M, down $0.5M
- Cash $1.9M; operating cash use $18.1M, financing cash provided $16.5M
- Runway into 2028 projected; additional funding needed, with clinical and development costs expected to increase substantially
AI summary of the HURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.03: Creation of a Direct Financial Obligation
- $1.3 million borrowed through two $650,000 draws on the revolving credit facility
- Borrowings intended for general corporate purposes, increasing near-term liquidity
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for the three months ended September 30, 2026
- Corporate update accompanying the quarterly results
Item EX-99.1: Item EX-99.1
- Q3 2026 results: cash $1.9M, with $9.2M drawn on Parkview’s credit facility
- Parkview facility provided $5.6M during Q3, supporting operations without immediate equity dilution
Item 2.03: Creation of a Direct Financial Obligation
- Additional $1.5 million revolving-credit draw received November 2, 2026
- Proceeds intended for general corporate purposes, supporting near-term liquidity
AI summaries of HURA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HURA
Don't miss the next HURA filing
- Alerts as it files. A push when HURA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HURA, by share count.
- Ask anything. An AI agent that reads every HURA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bianco James A. | G | Nov 17, 2026 | 75,000 | - |
| Bianco James A. | G | May 28, 2026 | 150,000 | - |
| List Alan | A | Feb 12, 2026 | 156,240 | - |
| Ng George K | A | Feb 12, 2026 | 156,240 | - |
| MANUSO JAMES S J | A | Feb 12, 2026 | 156,240 | - |
| Hoffman Robert E. | A | Feb 12, 2026 | 156,240 | - |
| Tendler Craig | A | Feb 12, 2026 | 156,240 | - |
| Bianco James A. | A | Jan 6, 2026 | 610,332 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | $0 | $0 |
| Net Income | -$29.3M | -$21.7M | -$30.1M |
| Balance Sheet | |||
| Total Assets | $4.4M | $20.0M | $27.4M |
| Equity | - | $14.6M | $20.9M |
| ROE | - | -148.6% | -143.6% |
| Per Share | |||
| EPS | $-2.47 | $-1.21 | $-0.63 |
| Cash Flow | |||
| Operating CF | -$12.0M | -$14.7M | -$27.6M |
| CapEx | $79K | $58K | $76K |
Source: XBRL data in TuHURA Biosciences, Inc./NV (HURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HURA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 17 | $9.5M |
| Q2 2026 | 17 | $14.9M |
| Q1 2026 | 19 | $12.0M |
| Q4 2025 | 18 | $3.8M |
| Q3 2025 | 17 | $11.4M |
| Q2 2025 | 17 | $10.8M |
| Q1 2025 | 8 | $8.0M |
| Q4 2024 | 6 | $3.9M |
- Bank of America Corp+204.3K (+481%)
- State Street Corp+4.2K (+2%)
- Northern Trust−1.53M (-94%)
- AQR Capital Management−313.7K (-74%)
- Millennium Management−173.2K (-38%)
- Citadel Advisors LLC−170.6K (-73%)
- Morgan Stanley−128.4K (-90%)
- Fifth Third Bancorp+521.6K
- Citigroup+1
- FMR LLC (Fidelity)−24.7K
- HANCOCK WHITNEY CORP−10.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 119 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HURA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | - | - |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 29, 2026 | - | - | |
| 8-K | May 15, 2026 | - | - | |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | - | - |
| 8-K | Apr 22, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
HURA SEC filings: frequently asked questions
Which institutions hold HURA stock?
As of September 30, 2026, the largest TuHURA Biosciences, Inc./NV (HURA) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.7 million), BlackRock ($1.2 million), Fifth Third Bancorp ($1.1 million), Millennium Management ($591,000), Bank of America Corp ($518,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HURA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and a net loss of $30.1 million. Diluted EPS was -$0.63. The figures come from the XBRL data in the 10-K.
What did HURA report in its latest 8-K?
TuHURA Biosciences, Inc./NV (HURA) filed an 8-K on November 18, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation). $1.3 million borrowed through two $650,000 draws on the revolving credit facility.
What are the latest HURA SEC filings?
TuHURA Biosciences, Inc./NV (HURA) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 18, 2026.
What is HURA's SEC CIK number?
TuHURA Biosciences, Inc./NV (HURA)'s SEC Central Index Key (CIK) is 1498382. EDGAR lists every HURA filing under that number.
Ask anything about HURA
The research agent reads HURA's filings, financials, insider trades and 13F holders, then answers with sources.